Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT05933070 Terminated - Cancer Clinical Trials

A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

LAUREL
Start date: June 15, 2020
Phase: Phase 1
Study type: Interventional

INMB-INB16-002 is a Phase I open-label, dose escalation study of INKmune therapy in subjects with myelodysplastic syndrome (MDS) with excess blasts without Auer rods (EB-1 or 2, or CMML 1 or 2) or subjects with acute myeloid leukaemia (AML) in complete remission.

NCT ID: NCT05919199 Enrolling by invitation - Clinical trials for Acute Myeloid Leukemia

PET Tracer Based FDG Signal for Predicting Prognosis in Acute Myeloid Leukemia

FDG-PETAML
Start date: January 3, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the predictive value of 18F-FDG PET probe signal in de novo diagnosed or refractory/relapsed patients with acute myeloid leukemia. It is hypothesized that the intensity of 18F-FDG signal, an indicator of glucose uptake capacity, in various cell subsets of bone marrow will improve the predictive effect of clinical standard prognostic work-up.

NCT ID: NCT05918692 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

Start date: July 26, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

NCT ID: NCT05918198 Recruiting - Clinical trials for Acute Myeloid Leukemia

Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the safety and efficacy of venetoclax plus CAG regimen in refractory/relapsed acute myeloid leukemia patients.

NCT ID: NCT05909293 Recruiting - Clinical trials for Acute Myeloid Leukemia

Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission

Start date: April 12, 2023
Phase: N/A
Study type: Interventional

This clinical study evaluates the efficacy and safety of maintenance therapy with BCL-2 inhibitors in elderly patients with acute myeloid leukemia (AML) in first complete remission. This study involves the following content: BCL-2 inhibitors.

NCT ID: NCT05904106 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

VINCENT
Start date: August 2023
Phase: Phase 2
Study type: Interventional

This phase II clinical trial evaluates the efficacy and tolerability of the non-intensive treatment with venetoclax and the hypomethylating agent azacitidine as compared to the standard of care chemotherapy plus gemtuzumab ozogamicin in newly diagnosed NPM1 mutated AML patients fit for intensive chemotherapy.

NCT ID: NCT05895201 Withdrawn - Clinical trials for Acute Myeloid Leukemia

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Start date: November 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label Phase I-II study to determine the safe doses of bortezomib, sitagliptin, and PTCy (Phase I) with expansion into a phase II trial to determine efficacy in improving survival.

NCT ID: NCT05893472 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.

Start date: April 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of the combination of venetoclax and HAA regimen in young, newly diagnosed acute myeloid leukemia patients under the age of 60.

NCT ID: NCT05893329 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Start date: June 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety, efficacy and pharmacokinetics of mitoxantrone hydrochloride liposome injection combined with chemotherapy in previously untreated de novo acute myeloid leukemia.

NCT ID: NCT05875805 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

A Telehealth Advance Care Planning Intervention

TeleSICP
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.